Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19

By sjmartinez • January 21, 2023

Taiwo BO, Chew KW, Moser C, Wohl DA, Daar ES, Li JZ, Greninger AL, Bausch C, Luke T, Hoover K, Neytman G, Giganti MJ, Olefsky M, Javan AC, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM; ACTIV-2/A5401 Study Team. Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19. J Infect Dis. 2023 Jan 20:jiad013. doi: 10.1093/infdis/jiad013. Epub ahead of print. PMID: 36661240.

Tags: antibody, covid-19, Infectious Diseases, polyclonal, Publications, SAB-185, transchromosomic, Treatment

The obstacle is the way: Finding a path to hepatitis C elimination

Lo Re V 3rd, Price JC, Schmitt S, Terrault N, Bhattacharya D, Arohnson A. The obstacle is the way: Finding a path to hepatitis C[...]

Severe Acute Respiratory Syndrome Coronavirus 2 Infection Alters Mediators of Lung Tissue Remodeling In Vitro and In Vivo

Wong M, Gain C, Sharma MB, Fotooh Abadi L, Hugo C, Vassilopoulos H, Daskou M, Fishbein GA, Kelesidis T. Severe Acute Respiratory Syndrome Coronavirus 2[...]

Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman[...]